智通财经APP讯,山东新华制药股份(00719)公布,近日,公司收到国家药品监督管理局核准签发的布洛芬混悬滴剂(15ml:0.6g,30ml:1.2g)《药品注册证书》。
新华制药的布洛芬混悬滴剂(15ml:0.6g,30ml:1.2g)于2025年5月取得药品注册证书,丰富了公司布洛芬制剂剂型,有利于强化配套生产优势,提升公司综合竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.